Journey Medical
Journey Medical's revenue rose 10.2% to $62 million in fiscal 2025. Its operating margin was −13.2%, up from −24.4% a year earlier. The diluted share count rose 19.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Journey Medical does
Journey Medical sells prescription skin-care drugs in the United States. It has eight FDA-approved products for skin conditions. The main ones are Emrosi, a low-dose minocycline capsule for the bumps and pimples of rosacea; Qbrexza, a medicated wipe for heavy underarm sweating; Accutane, a pill for severe acne; and Amzeeq and Zilxi, antibiotic foams for acne and rosacea. It also sells a few older products.
Journey mostly buys or licenses rights to drugs that others developed, then sells them through its own sales force, which calls on dermatologists. It sells mainly to specialty pharmacies and independent wholesalers rather than through the large national drug wholesalers. Emrosi, developed with Dr. Reddy's Laboratories, which also makes it, went on sale in April 2025. Revenue was $61.2 million in 2025, up 11%, as Emrosi sales offset lower Accutane sales amid competition.
Journey is controlled by Fortress Biotech, which holds majority voting control through a special class of shares. It had 58 full-time employees in March 2026 and is based in Scottsdale, Arizona. It plans to launch an anti-itch product bought from Sun Pharmaceutical in the first half of 2026.
Its biggest risks, as it describes them
- Sales of its skin drugs may fall as they face generic competition and lose patent protection.
- Its reliance on its field sales force, and on Dr. Reddy's to make and supply Emrosi.
- There is substantial doubt about its ability to continue as a going concern, and it may need to raise money on poor terms.
- Insurers and government payers may limit coverage or prices for its drugs.
- Its growth depends on finding and buying or licensing new products and fitting them into its business.
Income statement
Journey Medical lost money in fiscal 2025: a net loss of $11 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 49 | 32 | 27 | 20 | 24 |
| Debt incl. finance leases | — | 28 | 15 | 25 | 25 |
| Net debt (negative means net cash) | — | −4 | −13 | 5 | 1 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 1.6x | 0.7x | 1.2x | 0.8x |
| Interest coverage | −5.0x | −13.6x | −1.2x | −5.1x | −2.2x |
| Current ratio | 1.6x | 1.2x | 1.4x | 1.4x | 1.8x |
| Quick ratio | 1.4x | 0.9x | 1.1x | 1.0x | 1.5x |
Cash flow
Projections
Project Journey Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Journey Medical reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 2 of 9 | 5 of 9 |
| Rule of 40 | 7.8% | −72.1% | — |
| Altman Z'' | −1.63 | −3.27 | −1.40 |
| Accruals ratio | −10.0% | −7.1% | 1.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 6 of 9 | 2 of 9 | 5 of 9 |
Compare
Put Journey Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Journey Medical | FY25 | 10.2% | −13.2% | — | −22.4% | — | 5 | |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
| Enanta Pharmaceuticals | FY26 | −3.6% | −99.0% | −67.9% | — | — | — | Compare |
| Fortress Biotech | FY25 | 9.7% | −111.0% | — | −323.7% | — | 6 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 44 | 63 | 74 | 79 | 56 | 62 |
| Revenue growth | — | 41.8% | 16.7% | 7.5% | −29.1% | 10.2% |
| Gross profit | 30 | 31 | 43 | 56 | 35 | 41 |
| Research and development | — | 3 | 11 | 8 | 10 | 0 |
| Operating income | 8 | −35 | −28 | −2 | −14 | −8 |
| Net income | 5 | −44 | −30 | −4 | −15 | −11 |
| Diluted EPS (US$) | 0.49 | −4.32 | −1.69 | −0.21 | −0.72 | −0.47 |
| Diluted shares (millions) | 11 | 10 | 18 | 18 | 20 | 24 |
| Cash flow | ||||||
| Cash from operations | 5 | −2 | −14 | 5 | −9 | −12 |
| Capital expenditure | — | — | 20 | 5 | 15 | — |
| Free cash flow | — | — | −34 | 0 | −24 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 4 | 3 | 6 | 6 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 8 | 49 | 32 | 27 | 20 | 24 |
| Debt incl. finance leases | — | — | 28 | 15 | 25 | 25 |
| Total assets | 52 | 97 | 105 | 77 | 80 | 95 |
| Total liabilities | 42 | 55 | 88 | 56 | 60 | 63 |
| Shareholders' equity | 10 | 42 | 17 | 20 | 20 | 32 |
| Margins and ratios | ||||||
| Gross margin | 67.2% | 49.2% | 58.2% | 71.1% | 62.8% | 66.2% |
| Operating margin | 17.6% | −55.2% | −37.4% | −2.6% | −24.4% | −13.2% |
| Net margin | 11.9% | −69.7% | −40.2% | −4.9% | −26.1% | −18.5% |
| Free cash flow margin | — | — | −45.5% | 0.3% | −43.0% | — |
| Rule of 40 (growth + FCF margin) | — | — | −28.8% | 7.8% | −72.1% | — |
| Return on capital | — | — | — | −16.1% | −67.2% | −22.4% |
| Return on equity | — | −168.1% | −100.4% | −20.6% | −72.6% | −44.0% |
| Return on assets | — | −59.0% | −29.3% | −4.2% | −18.7% | −13.1% |
| Net debt to EBITDA | — | — | — | — | — | — |